CGEM · Cullinan Therapeutics, Inc.
Market Cap
$1.33B
Shares
64.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.59
Open$21.16
Day$20.10–21.34
52W close$5.75–22.95
Avg vol 30d727K
Short int10.4M · 16.1% float · 15.5d
Short vol76%
DataJan 2021–Sep 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$204.69M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$334.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.5%
Year over year · more shares
Price change (1Y)
+211.0%
Trailing year
Short interest
16.1%
Latest settlement · 15.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+38%
above
Price vs 50-day avg
+6%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
86%
near high
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+62%
trailing
YTD return
+99%
this year
Relative strength
+44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
16.12% of float · ▼ -2.0% MoM · 15.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
184 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−255%
Y/Y
Free cash flow
$-175.8M
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+38%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
86%
Bullish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $19 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
16.12% of float · ▼ -2.0% MoM · 15.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
184 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $21 · 86%
Range high $23
vs 200-day avg +38%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGEM
this stock
Cullinan Therapeutics, Inc.
|
$1.33B | +98.9% | -100.0% | — | 16.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Investor Relations
Latest news
Cullinan Therapeutics to Host Vir…
- Published
- Sep 10, 2026
- Upcoming events
- 1
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGEM | -7.1% | +4.8% | +61.6% | -6.7% | +98.9% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -5.9% | +6.6% | +43.8% | -6.4% | +86.9% |